glp-1 and diabetes Targeting GLP-1, GIP & GCG in Obesity Type 2 Research GLP-1-based therapies for diabetes, obesity
Description
Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
But as more people take these medications, one question keeps coming up: Am I losing too much muscle along with fat? The concern isnt just cosmetic
Per serving: ~240 cal | 22g protein | 6g fiber
Routine Consistency Small, simple eating or oral care routines can restore a sense of normalcy during periods of nausea or taste change
